SANIFIT Email Format

BiotechnologyBalearic Islands, Spain11-50 Employees

Sanifit is a biopharmaceutical company focused on developing SNF472, an experimental drug aimed at treating cardiovascular diseases associated with vascular calcification in patients with end-stage renal disease undergoing haemodialysis. Founded in 2007 as a spin-off from the University of the Balearic Islands, the company is based on the 2nd Floor Palma in the Balearic Islands region of Spain and operates a presence in the United States through a subsidiary established in San Diego. Its activities are centered on advancing therapies for calcification-related conditions, with ongoing Phase II programs in end-stage renal disease and in calciphylaxis, following completed Phase I studies. In the market, Sanifit targets clinicians and healthcare systems involved in cardio-renal care, addressing disorders linked to vascular calcification in the ESRD population. A notable recent development involves the company’s affiliation with Vifor Pharma, reflecting strategic corporate moves in the cardio-renal space, including a transition of Sanifit through acquisition-related milestones in 2021–2022.

Sign up for free to view info

Company overview Employee directory